HC Wainwright Reaffirms Buy Rating for Gracell Biotechnologies

GRCLDelisted Stock  USD 4.02  0.26  6.07%   
About 62% of Gracell Biotechnologies' investor base is looking to short. The analysis of current outlook of investing in Gracell Biotechnologies suggests that many traders are alarmed regarding Gracell Biotechnologies' prospects. Gracell Biotechnologies' investing sentiment shows overall attitude of investors towards Gracell Biotechnologies.
  
HC Wainwright restated their buy rating on shares of Gracell Biotechnologies in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has a 12.00 target price on the stock. Gracell Biotechnologies Stock Up 4.3 percent GRCL stock traded up 0.09 during trading hours on Thursday, reaching

Read at thelincolnianonline.com
news
  

Gracell Biotechnologies Fundamental Analysis

We analyze Gracell Biotechnologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gracell Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gracell Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Debt To Equity

Debt To Equity Comparative Analysis

Gracell Biotechnologies is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Gracell Biotechnologies Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Gracell Biotechnologies stock to make a market-neutral strategy. Peer analysis of Gracell Biotechnologies could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics with similar companies.

Peers

Gracell Biotechnologies Related Equities

GLUEMonte Rosa   13.72   
0%
100.0%
XFORX4 Pharmaceuticals   11.43   
0%
83.0%
CTMXCytomX Therapeutics   3.92   
0%
28.0%
BOLTBolt Biotherapeutics   1.59   
0%
11.0%
DAWNDay One   1.53   
0%
11.0%
BPMCBlueprint Medicines   1.35   
0%
9.0%
SPROSpero Therapeutics   0.88   
0%
6.0%
DSGNDesign Therapeutics   0.50   
0%
3.0%
ABOSAcumen Pharmaceuticals   0.44   
0%
3.0%
INZYInozyme Pharma   0.37   
2.0%
0%
TERNTerns Pharmaceuticals   1.58   
11.0%
0%
ERASErasca   2.05   
14.0%
0%
CHRSCoherus BioSciences   3.17   
23.0%
0%
AMLXAmylyx Pharmaceuticals   3.48   
25.0%
0%
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Other Consideration for investing in Gracell Stock

If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
Global Correlations
Find global opportunities by holding instruments from different markets
Transaction History
View history of all your transactions and understand their impact on performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules